Misoone (Misoprostol)

Misoprostol works by binding to prostaglandin E1 (EP) receptors. In the stomach, this stimulates mucus and bicarbonate secretion, protecting the lining. In the uterus, EP‑receptor activation raises intracellular calcium, causing smooth‑muscle contraction and cervical softening, which underlies its therapeutic effects.

The appropriate dose of Misoone is determined by the prescribing clinician based on the specific indication, patient characteristics, and local guidelines. Dosage regimens vary for ulcer prevention, labor induction, medical abortion, and cervical ripening, and should not be altered without medical advice.

Misoprostol is contraindicated for routine use during pregnancy unless it is being employed for a medically indicated purpose such as labor induction or abortion under professional supervision. Breastfeeding mothers should discuss risks with their healthcare provider, as the drug may be excreted in milk.

To order Misoone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Misoone (misoprostol) is a synthetic prostaglandin E1 analog, whereas other agents such as dinoprostone are prostaglandin E2 analogs. Misoprostol is more stable at room temperature and can be administered orally, offering flexibility, while E2 analogs often require vaginal or intracervical routes.

Misoone should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Misoone is administered orally, typically as a tablet or capsule, according to the prescriber's instructions. The drug is swallowed with water and should be taken on an empty stomach for ulcer prevention, while dosing schedules differ for obstetric indications.

Serious risks associated with misoprostol include uterine rupture, severe hemorrhage, and allergic reactions such as anaphylaxis. Patients should be monitored for signs of excessive uterine activity, heavy bleeding, or systemic hypersensitivity, and medical attention should be sought immediately if these occur.

Misoone should be avoided in individuals with known hypersensitivity to misoprostol or other prostaglandin analogs, in patients with active cardiovascular disease where uterine contraction may pose a risk, and in women with a prior uterine scar unless specifically indicated by a specialist.